Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
10 participants
Study Classification
INTERVENTIONAL
Study Start Date
2015-07-31
Study Completion Date
2017-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Hypothesis: Cortical spreading depolarizations are inhibited by the NMDA receptor antagonist Ketamine Aim 1: To demonstrate, in a group of patients with acute severe brain injury requiring surgery including traumatic brain injury and aneurysmal subarachnoid hemorrhage, whether use of continuous infusion of ketamine decreases frequency of occurrence of cortical spreading depolarizations.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Anaesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury
NCT05095857
Subarachnoid Hemorrhage, Aneurysmal
Intracerebral Hemorrhage
Traumatic Brain Injury
RECRUITING
PHASE4
Ketamine in Severe Traumatic Brain Injury
NCT06062628
Traumatic Brain Injury
Traumatic Encephalopathy
RECRUITING
EARLY_PHASE1
Effect of Ketamine (Ketalar) on Intracranial Pressure
NCT00437814
Traumatic Brain Injury
Intracranial Hypertension
UNKNOWN
NA
Pilot Study of Ketamine Sedation for Aneurysmal Subarachnoid Hemorrhage
NCT05032118
Subarachnoid Hemorrhage, Aneurysmal
WITHDRAWN
PHASE2/PHASE3
Emergency Ketamine Treatment of Suicidal Ideation
NCT02183272
Depression
Suicidal Ideation
Suicidal Impulses
UNKNOWN
PHASE2/PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Cortical spreading depolarizations (CSD) are massive events which recently have been observed in many types of acute brain injury and likely lead to expansion of injury. These "brain tsunamis" are unlike any other type of brain electrical event (such as seizures or normal neuronal transmission) in that they progress very slowly across the surface of the brain (2-5mm/minute) and involve near complete depolarization of the neurons and other cells. The only similar event in neurophysiology is an anoxic depolarization, which is the final wave of loss of cell function preceding death in cells suffering severe, irreversible hypoxia or ischemia(1). In the case of CSD, the cell is able to recover function, however, at an enormous metabolic expense. Massive amounts of energy substrate (ATP, glucose, oxygen) as well as the delivery system to bring these substrates (blood flow) are required to restore the normal ionic gradient of the cell membrane and cell function. Because of this loss of function of cells, normal electrocortical (ECog) activity is transiently lost, resulting in a depression of the high frequency cortical activity, which is why the phenomenon is also frequently referred to as "cortical spreading depression." CSD has been definitively documented to occur after many types of acute brain injury including ischemic stroke, aneurysmal subarachnoid hemorrhage, intracerebral hemorrhage, and severe traumatic brain injury(2,3). The true incidence is, for the time being, unknown, in that the measurement technique requires placement of a small cortical electrode at the time of a surgical procedure. This limits the region of measurement to relatively small area in patients undergoing surgery, however even in this very small sample, the incidence of delayed SD after brain injury ranges from 53-88%(4). Efforts are underway to attempt to measure CSD less invasively(5) or non-invasively(6,7), however these techniques are currently under exploration and do not have the robust reliability of the cortical electrode system.
Mounting human data coupled with extensive animal data supports the assertion that CSD is not only a marker in response to severe brain injury, but in fact, plays a causal role in injury propagation(8). Animal data is fairly definitive in this assertion, in that CSD can be studied in uninjured brain and inducing CSD leads to neuronal death, particularly with repeated events. Note the progressive loss of brain electrical activity with repeated CSD in the figure to the right. In animal models, CSD clearly leads to expansion of injury, particularly in ischemic stroke models. Human data is unavoidably observational to this point, however by observing multiple physiologic modalities, the deleterious effects become clear. A spectrum of local blood flow responses to CSD have been observed, ranging from a wave of hyperemia (termed the normal hemodynamic response) to a wave of ischemia (termed the inverse hemodynamic response(9, 10)). The factors that determine the response likely have to do with the availability of substrate (glucose, oxygen) and delivery (blood flow) coupled with the baseline metabolic state of the tissue (depressed metabolic state may be more resistant). When the inverse hemodynamic response is observed, an associated wave of tissue hypoxia is observed, which becomes linearly more hypoxic with repeated CSD in a short interval(11). Brain metabolism also can be measured during CSD, and consistent metabolic challenge is noted, with increased micro dialysis lactate and decreased glucose(12). In the case of repeated events, this glucose depletion becomes progressive due to inadequate time for the tissue to recover between these massive events leading to progressive ischemia(12).
From a clinical perspective, the metabolic data can support a deleterious effect, but the effect on clinical outcome is critical in determining if the events are relevant as a potential target for therapy. The occurrence and severity of CSD has been closely linked to both development of new stroke as well as clinical outcome in both retrospective and prospective series. In subarachnoid hemorrhage, Dreier(13) reported a direct association with clinical delayed ischemic neurologic defect (DIND) and the presence of a cluster of SD. Furthermore, in this small series, the patients who went on to develop stroke had markedly longer periods of depression, indicating inability of the tissue to recover from the event compared to patients without delayed stroke. The most extensive clinical outcome data is from traumatic brain injury (TBI)(14,15) where the presence of any CSD showed a non-significant trend toward predicting worse outcome, however CSD occurring in already dysfunctional tissue (termed isoelectric spreading depolarization or ISD) was stronger predictor of clinical outcome than a composite score of most standard variables through to predict outcome (OR 7.58 (95%CI 2.64-21.8) for ISD compared to 1.76(95%CI 1.26-2.46) for the composite prognostic score)(15).
This mounting observational data as to the deleterious effects of CSD has led to increased excitement regarding CSD as a novel target for prevention of delayed injury after diverse types of acute brain injury(16). The optimal target or agent has not been defined, but there are promising animal data supporting a wide variety of agents, primarily targeting NMDAVR, as this is thought to be an important factor in propagation of SD(17). Initial clinical case reports of the effect of ketamine being used as sedation in patients with severe TBI(18) led to a larger scale effort to retrospectively study the various anesthetics used for standard clinical care on the frequency of CSD in monitored patients(19). Using only the sedation medications for which there were \>1000 cumulative hours of ECog recording while on that medication, the effects of propofol, fentanyl, midazolam, ketamine, morphine, and sufentanyl were examined. The study found a consistent effect of ketamine in decreased probability of CSD/h per patient. This was nearly linearly dose dependent, and importantly, in multivariate analysis, ketamine still emerged as having a significant effect on decreasing both occurrence of CSD as well as the occurrence of the more deleterious clusters of CSD(19).
Though ongoing observational data is still clearly needed to better characterize the susceptibility and effects of CSD, in order to move toward trial of CSD directed therapy, a prospective trial of the effect of ketamine on the occurrence of CSD is necessary to confirm these retrospective observations and establish the precedent for future therapeutic trials. The SAKS trial will provide important confirmatory pilot data to direct the implementation of future trials.
This is a prospective, randomized, controlled, multiple cross-over trial evaluating the efficacy of ketamine in the suppression of CSDs. This multiple crossover design was chosen in order to be able to develop preliminary data which could guide implementation of future multicenter trials. Because of the significant variability between patients, a study randomized by patients would be subject to a large amount of potential bias. Because factors such as time of day or hospital day also are known to affect CSD, a brief crossover period of 6 hours was chosen. The study will be registered with clinicaltrials.gov prior to enrollment of patients. Patients with severe traumatic brain injury or subarachnoid hemorrhage who fit the inclusion/exclusion criteria will be approached by either research coordinators or study investigators who will consent the LAR for the study prior to clinically indicated craniotomy. It is not expected that patients will be able to independently consent given the severity of the condition, however, if the patient is conscious, attempts will be made to discuss the study with him or her as well.
The patient's surgical procedure will be carried out as planned. The only alteration of the surgical procedure will be the placement of a subdural electrode strip (1x6 cortical strip: Integra: Plainsboro, NJ) on the brain cortex adjacent to the operative site at the end of the procedure. These strips are standard, FDA approved, disposable, pre-sterilized devices used routinely for epilepsy monitoring. In addition, the investigators have used these strips as part of our post-injury IRB approved protocol (10-159) for many days after surgery. The cortical strip (plus a dermal reference electrode on the mastoid or apex of the skull) will be monitored with a Moberg CNS monitor. (Moberg Research, Ampler, PA).The Moberg monitor is a modified version of a standard clinical use multiparametric monitoring system shown below which was cleared by the FDA in 2008. The only difference is the ECog amplifier, which allows for direct full frequency spectrum DC recording.
Upon arrival, post-operatively, to the Neurosciences Intensive Care Unit, the patient will have randomization completed via online randomization program. Randomization will be to allocate patients to either of two groups: 1) Ketamine first or 2) Propofol/other first. No secondary randomization criteria are thought to be necessary given the small sample size for this pilot trial. Initiation of the protocoled sedation regimen will begin on the next hour divisible by 6 (i.e. 06:00, 12:00, 18:00, 24:00). The randomization will determine which sedative to start, and after that the ketamine and propofol/other infusions will be alternated every 6 hours on the above schedules.
Dosages of these sedating medications will not be standardized, but rather titrated to clinical effect. The clinical effect will be determined by the attending intensivist based on the patient's clinical needs. This level of sedation will be communicated to nursing via the Riker Sedation-Agitation Score(20). A minimal dose of ketamine (0.1mg/min or 6mg/hr) will be infused during the ketamine periods, which is lower than required to induce sedation. No minimal sedation requirements will exist for the propofol or other regimen period. This will be done to test the effect of ketamine (which is hypothesized to affect frequency of SD) compared to other sedations regimens (which are not thought to affect SD.) Each period of adjustment of the sedation regimen will be treated as a "spontaneous breathing trial" which is a common standard of care procedure for nursing which involves holding sedation to determine a patient's neurologic exam and respiratory ability with subsequent titration back to appropriate clinical effect. These sedation breaks are very common in the ICU and titration to the desired clinical effect will be performed with the appropriate drug per the standard ICU nursing protocols. In the event that the patient no longer needs invasive positive pressure ventilation prior to discontinuation of \] neuromonitoring, propofol/other sedation intervals will not have mandatory sedative infusions, however, ketamine intervals will have a basal dose of 0.1mg/min (6mg/hr). 'The sedation protocol will end when the strip is removed. This is determined by the patients critical care needs. The strip is checked daily for function as well as any sign of problem such as leak of CSF. Once other critical care monitoring is discontinued (such as ventricular drains and invasive monitoring) the strip will be removed. Other endpoints will include any sign of CSF leak, adverse event reported, or treating intensivist does not think alternating sedation is safe.
During the sedation protocol, cortical electroencephalographic monitoring with the cortical electrodes will be continuously recording. Other physiologic data obtained clinically (including, but not limited to, vital signs, arterial wave forms, laboratory values, video EEG) will be subject to review and data collection for correlation with occurrence of SD. This data is obtained as part of standard of care and stored in a departmental server in an anonymous fashion. Clinical video EEG will be obtained on the majority of patients (if not all patients) as part of standard multimodal monitoring. This video will be reviewed to look for any external stimuli that might induce cortical spreading depressions.
Mounting human data coupled with extensive animal data supports the assertion that CSD is not only a marker in response to severe brain injury, but in fact, plays a causal role in injury propagation(8). Animal data is fairly definitive in this assertion, in that CSD can be studied in uninjured brain and inducing CSD leads to neuronal death, particularly with repeated events. Note the progressive loss of brain electrical activity with repeated CSD in the figure to the right. In animal models, CSD clearly leads to expansion of injury, particularly in ischemic stroke models. Human data is unavoidably observational to this point, however by observing multiple physiologic modalities, the deleterious effects become clear. A spectrum of local blood flow responses to CSD have been observed, ranging from a wave of hyperemia (termed the normal hemodynamic response) to a wave of ischemia (termed the inverse hemodynamic response(9, 10)). The factors that determine the response likely have to do with the availability of substrate (glucose, oxygen) and delivery (blood flow) coupled with the baseline metabolic state of the tissue (depressed metabolic state may be more resistant). When the inverse hemodynamic response is observed, an associated wave of tissue hypoxia is observed, which becomes linearly more hypoxic with repeated CSD in a short interval(11). Brain metabolism also can be measured during CSD, and consistent metabolic challenge is noted, with increased micro dialysis lactate and decreased glucose(12). In the case of repeated events, this glucose depletion becomes progressive due to inadequate time for the tissue to recover between these massive events leading to progressive ischemia(12).
From a clinical perspective, the metabolic data can support a deleterious effect, but the effect on clinical outcome is critical in determining if the events are relevant as a potential target for therapy. The occurrence and severity of CSD has been closely linked to both development of new stroke as well as clinical outcome in both retrospective and prospective series. In subarachnoid hemorrhage, Dreier(13) reported a direct association with clinical delayed ischemic neurologic defect (DIND) and the presence of a cluster of SD. Furthermore, in this small series, the patients who went on to develop stroke had markedly longer periods of depression, indicating inability of the tissue to recover from the event compared to patients without delayed stroke. The most extensive clinical outcome data is from traumatic brain injury (TBI)(14,15) where the presence of any CSD showed a non-significant trend toward predicting worse outcome, however CSD occurring in already dysfunctional tissue (termed isoelectric spreading depolarization or ISD) was stronger predictor of clinical outcome than a composite score of most standard variables through to predict outcome (OR 7.58 (95%CI 2.64-21.8) for ISD compared to 1.76(95%CI 1.26-2.46) for the composite prognostic score)(15).
This mounting observational data as to the deleterious effects of CSD has led to increased excitement regarding CSD as a novel target for prevention of delayed injury after diverse types of acute brain injury(16). The optimal target or agent has not been defined, but there are promising animal data supporting a wide variety of agents, primarily targeting NMDAVR, as this is thought to be an important factor in propagation of SD(17). Initial clinical case reports of the effect of ketamine being used as sedation in patients with severe TBI(18) led to a larger scale effort to retrospectively study the various anesthetics used for standard clinical care on the frequency of CSD in monitored patients(19). Using only the sedation medications for which there were \>1000 cumulative hours of ECog recording while on that medication, the effects of propofol, fentanyl, midazolam, ketamine, morphine, and sufentanyl were examined. The study found a consistent effect of ketamine in decreased probability of CSD/h per patient. This was nearly linearly dose dependent, and importantly, in multivariate analysis, ketamine still emerged as having a significant effect on decreasing both occurrence of CSD as well as the occurrence of the more deleterious clusters of CSD(19).
Though ongoing observational data is still clearly needed to better characterize the susceptibility and effects of CSD, in order to move toward trial of CSD directed therapy, a prospective trial of the effect of ketamine on the occurrence of CSD is necessary to confirm these retrospective observations and establish the precedent for future therapeutic trials. The SAKS trial will provide important confirmatory pilot data to direct the implementation of future trials.
This is a prospective, randomized, controlled, multiple cross-over trial evaluating the efficacy of ketamine in the suppression of CSDs. This multiple crossover design was chosen in order to be able to develop preliminary data which could guide implementation of future multicenter trials. Because of the significant variability between patients, a study randomized by patients would be subject to a large amount of potential bias. Because factors such as time of day or hospital day also are known to affect CSD, a brief crossover period of 6 hours was chosen. The study will be registered with clinicaltrials.gov prior to enrollment of patients. Patients with severe traumatic brain injury or subarachnoid hemorrhage who fit the inclusion/exclusion criteria will be approached by either research coordinators or study investigators who will consent the LAR for the study prior to clinically indicated craniotomy. It is not expected that patients will be able to independently consent given the severity of the condition, however, if the patient is conscious, attempts will be made to discuss the study with him or her as well.
The patient's surgical procedure will be carried out as planned. The only alteration of the surgical procedure will be the placement of a subdural electrode strip (1x6 cortical strip: Integra: Plainsboro, NJ) on the brain cortex adjacent to the operative site at the end of the procedure. These strips are standard, FDA approved, disposable, pre-sterilized devices used routinely for epilepsy monitoring. In addition, the investigators have used these strips as part of our post-injury IRB approved protocol (10-159) for many days after surgery. The cortical strip (plus a dermal reference electrode on the mastoid or apex of the skull) will be monitored with a Moberg CNS monitor. (Moberg Research, Ampler, PA).The Moberg monitor is a modified version of a standard clinical use multiparametric monitoring system shown below which was cleared by the FDA in 2008. The only difference is the ECog amplifier, which allows for direct full frequency spectrum DC recording.
Upon arrival, post-operatively, to the Neurosciences Intensive Care Unit, the patient will have randomization completed via online randomization program. Randomization will be to allocate patients to either of two groups: 1) Ketamine first or 2) Propofol/other first. No secondary randomization criteria are thought to be necessary given the small sample size for this pilot trial. Initiation of the protocoled sedation regimen will begin on the next hour divisible by 6 (i.e. 06:00, 12:00, 18:00, 24:00). The randomization will determine which sedative to start, and after that the ketamine and propofol/other infusions will be alternated every 6 hours on the above schedules.
Dosages of these sedating medications will not be standardized, but rather titrated to clinical effect. The clinical effect will be determined by the attending intensivist based on the patient's clinical needs. This level of sedation will be communicated to nursing via the Riker Sedation-Agitation Score(20). A minimal dose of ketamine (0.1mg/min or 6mg/hr) will be infused during the ketamine periods, which is lower than required to induce sedation. No minimal sedation requirements will exist for the propofol or other regimen period. This will be done to test the effect of ketamine (which is hypothesized to affect frequency of SD) compared to other sedations regimens (which are not thought to affect SD.) Each period of adjustment of the sedation regimen will be treated as a "spontaneous breathing trial" which is a common standard of care procedure for nursing which involves holding sedation to determine a patient's neurologic exam and respiratory ability with subsequent titration back to appropriate clinical effect. These sedation breaks are very common in the ICU and titration to the desired clinical effect will be performed with the appropriate drug per the standard ICU nursing protocols. In the event that the patient no longer needs invasive positive pressure ventilation prior to discontinuation of \] neuromonitoring, propofol/other sedation intervals will not have mandatory sedative infusions, however, ketamine intervals will have a basal dose of 0.1mg/min (6mg/hr). 'The sedation protocol will end when the strip is removed. This is determined by the patients critical care needs. The strip is checked daily for function as well as any sign of problem such as leak of CSF. Once other critical care monitoring is discontinued (such as ventricular drains and invasive monitoring) the strip will be removed. Other endpoints will include any sign of CSF leak, adverse event reported, or treating intensivist does not think alternating sedation is safe.
During the sedation protocol, cortical electroencephalographic monitoring with the cortical electrodes will be continuously recording. Other physiologic data obtained clinically (including, but not limited to, vital signs, arterial wave forms, laboratory values, video EEG) will be subject to review and data collection for correlation with occurrence of SD. This data is obtained as part of standard of care and stored in a departmental server in an anonymous fashion. Clinical video EEG will be obtained on the majority of patients (if not all patients) as part of standard multimodal monitoring. This video will be reviewed to look for any external stimuli that might induce cortical spreading depressions.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Cortical Spreading Depolarization
Cortical Spreading Depression
Subarachoid Hemorrhage
Traumatic Brain Injury
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
CROSSOVER
Primary Study Purpose
TREATMENT
Blinding Strategy
SINGLE
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ketamine first
Randomization to receive ketamine as first post-operative sedative in the Neuroscience Intensive Care unit. This group will cross-over to "other sedation" after 6 hours, then alternate every 6 hours between these groups during the entirety of invasive neuromonitoring.
Group Type
EXPERIMENTAL
ketamine
Intervention Type
DRUG
Ketamine will be used as a sedative alternative to other more conventional sedatives (such as propofol, versed, or dexmedetomidine) in 6 hour blocks of time. Ketamine will be titrated at the bedside based on clinically desired Riker Sedation-Agitation Scale target. Both groups will receive the drug in this multiple crossover design. The only difference between groups is which sedation regimen is started first to minimize any bias related to differences in physiology in the early post-operative phase.
Other sedation (typically propofol) first
Randomization to receive sedative other than ketamine as first post-operative sedative in the Neuroscience Intensive Care unit. This group will cross-over to ketamine after 6 hours, then alternate every 6 hours between these groups during the entirety of invasive neuromonitoring.
Group Type
EXPERIMENTAL
ketamine
Intervention Type
DRUG
Ketamine will be used as a sedative alternative to other more conventional sedatives (such as propofol, versed, or dexmedetomidine) in 6 hour blocks of time. Ketamine will be titrated at the bedside based on clinically desired Riker Sedation-Agitation Scale target. Both groups will receive the drug in this multiple crossover design. The only difference between groups is which sedation regimen is started first to minimize any bias related to differences in physiology in the early post-operative phase.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ketamine
Ketamine will be used as a sedative alternative to other more conventional sedatives (such as propofol, versed, or dexmedetomidine) in 6 hour blocks of time. Ketamine will be titrated at the bedside based on clinically desired Riker Sedation-Agitation Scale target. Both groups will receive the drug in this multiple crossover design. The only difference between groups is which sedation regimen is started first to minimize any bias related to differences in physiology in the early post-operative phase.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* GCS \<8
* SAH or severe traumatic brain injury requiring craniotomy
* Consent obtainable (via legal representative)
* Ictus (bleed or injury) within 48 hours of enrollment
* Clinically appropriate for multimodality monitoring
* SAH or severe traumatic brain injury requiring craniotomy
* Consent obtainable (via legal representative)
* Ictus (bleed or injury) within 48 hours of enrollment
* Clinically appropriate for multimodality monitoring
Exclusion Criteria
* Anticipated survival \<48 hours
* No craniotomy
* Infratentorial craniotomy only•Unable to obtain consent
* Absence of clinically used multimodality monitoring
* Prisoners
* Pregnant
* No craniotomy
* Infratentorial craniotomy only•Unable to obtain consent
* Absence of clinically used multimodality monitoring
* Prisoners
* Pregnant
Minimum Eligible Age
18 Years
Maximum Eligible Age
90 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of New Mexico
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Andrew Phillip Carlson
Assistant Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrew P Carlson, MD
Role: PRINCIPAL_INVESTIGATOR
University of New Mexico
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of New Mexico
Albuquerque, New Mexico, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Dreier JP, Isele T, Reiffurth C, Offenhauser N, Kirov SA, Dahlem MA, Herreras O. Is spreading depolarization characterized by an abrupt, massive release of gibbs free energy from the human brain cortex? Neuroscientist. 2013 Feb;19(1):25-42. doi: 10.1177/1073858412453340. Epub 2012 Jul 24.
Reference Type
BACKGROUND
Strong AJ, Fabricius M, Boutelle MG, Hibbins SJ, Hopwood SE, Jones R, Parkin MC, Lauritzen M. Spreading and synchronous depressions of cortical activity in acutely injured human brain. Stroke. 2002 Dec;33(12):2738-43. doi: 10.1161/01.str.0000043073.69602.09.
Reference Type
BACKGROUND
Fabricius M, Fuhr S, Bhatia R, Boutelle M, Hashemi P, Strong AJ, Lauritzen M. Cortical spreading depression and peri-infarct depolarization in acutely injured human cerebral cortex. Brain. 2006 Mar;129(Pt 3):778-90. doi: 10.1093/brain/awh716. Epub 2005 Dec 19.
Reference Type
BACKGROUND
Dohmen C, Sakowitz OW, Fabricius M, Bosche B, Reithmeier T, Ernestus RI, Brinker G, Dreier JP, Woitzik J, Strong AJ, Graf R; Co-Operative Study of Brain Injury Depolarisations (COSBID). Spreading depolarizations occur in human ischemic stroke with high incidence. Ann Neurol. 2008 Jun;63(6):720-8. doi: 10.1002/ana.21390.
Reference Type
BACKGROUND
Jeffcote T, Hinzman JM, Jewell SL, Learney RM, Pahl C, Tolias C, Walsh DC, Hocker S, Zakrzewska A, Fabricius ME, Strong AJ, Hartings JA, Boutelle MG. Detection of spreading depolarization with intraparenchymal electrodes in the injured human brain. Neurocrit Care. 2014 Feb;20(1):21-31. doi: 10.1007/s12028-013-9938-7.
Reference Type
BACKGROUND
Drenckhahn C, Winkler MK, Major S, Scheel M, Kang EJ, Pinczolits A, Grozea C, Hartings JA, Woitzik J, Dreier JP; COSBID study group. Correlates of spreading depolarization in human scalp electroencephalography. Brain. 2012 Mar;135(Pt 3):853-68. doi: 10.1093/brain/aws010.
Reference Type
BACKGROUND
Hartings JA, Wilson JA, Hinzman JM, Pollandt S, Dreier JP, DiNapoli V, Ficker DM, Shutter LA, Andaluz N. Spreading depression in continuous electroencephalography of brain trauma. Ann Neurol. 2014 Nov;76(5):681-94. doi: 10.1002/ana.24256. Epub 2014 Sep 17.
Reference Type
BACKGROUND
Nakamura H, Strong AJ, Dohmen C, Sakowitz OW, Vollmar S, Sue M, Kracht L, Hashemi P, Bhatia R, Yoshimine T, Dreier JP, Dunn AK, Graf R. Spreading depolarizations cycle around and enlarge focal ischaemic brain lesions. Brain. 2010 Jul;133(Pt 7):1994-2006. doi: 10.1093/brain/awq117. Epub 2010 May 26.
Reference Type
BACKGROUND
Dreier JP, Major S, Manning A, Woitzik J, Drenckhahn C, Steinbrink J, Tolias C, Oliveira-Ferreira AI, Fabricius M, Hartings JA, Vajkoczy P, Lauritzen M, Dirnagl U, Bohner G, Strong AJ; COSBID study group. Cortical spreading ischaemia is a novel process involved in ischaemic damage in patients with aneurysmal subarachnoid haemorrhage. Brain. 2009 Jul;132(Pt 7):1866-81. doi: 10.1093/brain/awp102. Epub 2009 May 6.
Reference Type
BACKGROUND
Hinzman JM, Andaluz N, Shutter LA, Okonkwo DO, Pahl C, Strong AJ, Dreier JP, Hartings JA. Inverse neurovascular coupling to cortical spreading depolarizations in severe brain trauma. Brain. 2014 Nov;137(Pt 11):2960-72. doi: 10.1093/brain/awu241. Epub 2014 Aug 24.
Reference Type
BACKGROUND
Bosche B, Graf R, Ernestus RI, Dohmen C, Reithmeier T, Brinker G, Strong AJ, Dreier JP, Woitzik J; Members of the Cooperative Study of Brain Injury Depolarizations (COSBID). Recurrent spreading depolarizations after subarachnoid hemorrhage decreases oxygen availability in human cerebral cortex. Ann Neurol. 2010 May;67(5):607-17. doi: 10.1002/ana.21943.
Reference Type
BACKGROUND
Feuerstein D, Manning A, Hashemi P, Bhatia R, Fabricius M, Tolias C, Pahl C, Ervine M, Strong AJ, Boutelle MG. Dynamic metabolic response to multiple spreading depolarizations in patients with acute brain injury: an online microdialysis study. J Cereb Blood Flow Metab. 2010 Jul;30(7):1343-55. doi: 10.1038/jcbfm.2010.17. Epub 2010 Feb 10.
Reference Type
BACKGROUND
Dreier JP, Woitzik J, Fabricius M, Bhatia R, Major S, Drenckhahn C, Lehmann TN, Sarrafzadeh A, Willumsen L, Hartings JA, Sakowitz OW, Seemann JH, Thieme A, Lauritzen M, Strong AJ. Delayed ischaemic neurological deficits after subarachnoid haemorrhage are associated with clusters of spreading depolarizations. Brain. 2006 Dec;129(Pt 12):3224-37. doi: 10.1093/brain/awl297. Epub 2006 Oct 25.
Reference Type
BACKGROUND
Hartings JA, Strong AJ, Fabricius M, Manning A, Bhatia R, Dreier JP, Mazzeo AT, Tortella FC, Bullock MR; Co-Operative Study of Brain Injury Depolarizations. Spreading depolarizations and late secondary insults after traumatic brain injury. J Neurotrauma. 2009 Nov;26(11):1857-66. doi: 10.1089/neu.2009.0961.
Reference Type
BACKGROUND
Hartings JA, Bullock MR, Okonkwo DO, Murray LS, Murray GD, Fabricius M, Maas AI, Woitzik J, Sakowitz O, Mathern B, Roozenbeek B, Lingsma H, Dreier JP, Puccio AM, Shutter LA, Pahl C, Strong AJ; Co-Operative Study on Brain Injury Depolarisations. Spreading depolarisations and outcome after traumatic brain injury: a prospective observational study. Lancet Neurol. 2011 Dec;10(12):1058-64. doi: 10.1016/S1474-4422(11)70243-5. Epub 2011 Nov 3.
Reference Type
BACKGROUND
Strong AJ, Hartings JA, Dreier JP. Cortical spreading depression: an adverse but treatable factor in intensive care? Curr Opin Crit Care. 2007 Apr;13(2):126-33. doi: 10.1097/MCC.0b013e32807faffb.
Reference Type
BACKGROUND
Sanchez-Porras R, Santos E, Scholl M, Stock C, Zheng Z, Schiebel P, Orakcioglu B, Unterberg AW, Sakowitz OW. The effect of ketamine on optical and electrical characteristics of spreading depolarizations in gyrencephalic swine cortex. Neuropharmacology. 2014 Sep;84:52-61. doi: 10.1016/j.neuropharm.2014.04.018. Epub 2014 May 4.
Reference Type
BACKGROUND
Sakowitz OW, Kiening KL, Krajewski KL, Sarrafzadeh AS, Fabricius M, Strong AJ, Unterberg AW, Dreier JP. Preliminary evidence that ketamine inhibits spreading depolarizations in acute human brain injury. Stroke. 2009 Aug;40(8):e519-22. doi: 10.1161/STROKEAHA.109.549303. Epub 2009 Jun 11.
Reference Type
BACKGROUND
Hertle DN, Dreier JP, Woitzik J, Hartings JA, Bullock R, Okonkwo DO, Shutter LA, Vidgeon S, Strong AJ, Kowoll C, Dohmen C, Diedler J, Veltkamp R, Bruckner T, Unterberg AW, Sakowitz OW; Cooperative Study of Brain Injury Depolarizations (COSBID). Effect of analgesics and sedatives on the occurrence of spreading depolarizations accompanying acute brain injury. Brain. 2012 Aug;135(Pt 8):2390-8. doi: 10.1093/brain/aws152. Epub 2012 Jun 19.
Reference Type
BACKGROUND
Riker RR, Picard JT, Fraser GL. Prospective evaluation of the Sedation-Agitation Scale for adult critically ill patients. Crit Care Med. 1999 Jul;27(7):1325-9. doi: 10.1097/00003246-199907000-00022.
Reference Type
BACKGROUND
Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. Anesth Analg. 2003 Dec;97(6):1730-1739. doi: 10.1213/01.ANE.0000086618.28845.9B.
Reference Type
BACKGROUND
Correll GE, Maleki J, Gracely EJ, Muir JJ, Harbut RE. Subanesthetic ketamine infusion therapy: a retrospective analysis of a novel therapeutic approach to complex regional pain syndrome. Pain Med. 2004 Sep;5(3):263-75. doi: 10.1111/j.1526-4637.2004.04043.x.
Reference Type
BACKGROUND
Elia N, Tramer MR. Ketamine and postoperative pain--a quantitative systematic review of randomised trials. Pain. 2005 Jan;113(1-2):61-70. doi: 10.1016/j.pain.2004.09.036.
Reference Type
BACKGROUND
Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney DS, Mathew SJ. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013 Oct;170(10):1134-42. doi: 10.1176/appi.ajp.2013.13030392.
Reference Type
BACKGROUND
Carlson AP, Abbas M, Alunday RL, Qeadan F, Shuttleworth CW. Spreading depolarization in acute brain injury inhibited by ketamine: a prospective, randomized, multiple crossover trial. J Neurosurg. 2018 May 25;130(5):1513-1519. doi: 10.3171/2017.12.JNS171665. Print 2019 May 1.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15-056
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Overcoming Membrane Transporters to Improve CNS Drug Delivery - Improving Brain Antioxidants After Traumatic Brain Injury
NCT01322009
COMPLETED
PHASE1/PHASE2
Mild Head Injury, Antiplatelets, and Anticoagulants
NCT04741334
COMPLETED
Improving Outcomes for Patients With Life-Threatening Neurologic Illness
NCT04189471
RECRUITING
Delayed Cerebral Infarction Beyond Endoluminal Spasmolysis and Induced Hypertension
NCT07305922
RECRUITING
Ketamine Infusion in Neurologic Deficit
NCT02636218
COMPLETED
PHASE2/PHASE3
Optimized Therapy in Severe Traumatic Brain Injured Patients
NCT02130674
COMPLETED
PHASE4
Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury
NCT00124293
COMPLETED
Ketamine for Sedation in Severe Traumatic Brain Injury
NCT06429657
SUSPENDED
PHASE4
Mild Traumatic Brain Injury and the Risk for Traumatic Intracranial Hemorrhage
NCT05609721
COMPLETED
Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department
NCT06085937
RECRUITING
PHASE1
Inhaled Nitric Oxide in Brain Injury
NCT03260569
COMPLETED
PHASE3
Ketogenic Diet for Traumatic Brain Injury
NCT03982602
COMPLETED
EARLY_PHASE1
Neuroprotective Effect of Dexomitomidine
NCT05487742
UNKNOWN
PHASE1
Ketogenic Diet & Functional Recovery in Moderate to Severe Traumatic Brain Injury
NCT04530032
COMPLETED
NA
The Influence of Noradrenaline on Coagulation and Fibrinolysis in Severe Isolated Brain Injury
NCT04515420
UNKNOWN
External Lumbar Drainage to Reduce ICP in Severe TBI: a Phase 1 Clinical Trial
NCT05889650
RECRUITING
NA
Aerosolized Endotracheal Lidocaine to Avoid Intracranial Pressure Spikes in Patients With Severe Traumatic Brain Injury
NCT05058677
COMPLETED
PHASE4
No Cases of Delayed Intracranial Hemorrhage (d-ICH) Among Patients With Mild Traumatic Brain Injury (mTBI) on Oral Anticoagulation Therapy
NCT05609734
COMPLETED
Cerebral Autoregulation and Vasospasm in Patients With TBI
NCT02351518
COMPLETED
Lumbar Drain vs Extraventricular Drain to Prevent Vasospasm in Subarachnoid Hemorrhage
NCT03065231
RECRUITING
NA
Use of Cerebral Biomarkers in Minor Traumatic Brain Injury in the Emergency Unit
NCT06069674
UNKNOWN
Stellate Block Versus Nimodipine Infusion for Traumatic Brain Injury
NCT05182619
UNKNOWN
EARLY_PHASE1
Targeting Spreading Depolarization After Chronic Subdural Hematoma Surgery (TASD)
NCT04966546
WITHDRAWN
EARLY_PHASE1
Dexmedetomidine on Brain Injury Patients
NCT06661980
COMPLETED
NA
Impact of Cardiac Blood Flow on Cerebral Blood Flow in Patients With Severe Traumatic Brain Injury
NCT02019810
UNKNOWN
PHASE2